J. Mendelsohn

发表

"Personalized Cancer Therapy": A Publicly Available Precision Oncology Resource.

Md Abu Shufean, Amber M. Johnson, Nora S. Sanchez, 2017, Cancer research.

A decision support framework for genomically informed investigational cancer therapy.

Amber M. Johnson, Ann M. Bailey, G. Mills, 2015, Journal of the National Cancer Institute.

Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody

J. Mendelsohn, Z. Fan, Bolin Liu, 2001, Oncogene.

A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer

Pierre Validire, Yudi Pawitan, Angel Porgador, 2015, Oncotarget.

Bioinformatics and systems biology

Gordon B Mills, Prahlad T. Ram, Prahlad T Ram, 2012, Molecular oncology.

The EGF receptor family as targets for cancer therapy

John Mendelsohn, J. Baselga, J. Mendelsohn, 2000, Oncogene.

Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation.

C. Macleod, J. Mendelsohn, B. Magun, 1986, Proceedings of the National Academy of Sciences of the United States of America.

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer.

J. Baselga, J. Mendelsohn, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

James Allison, Stephen Forman, Massimo Cristofanilli, 2015, Mayo Clinic proceedings.

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

D Tripathy, C. Hudis, L. Norton, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epidermal growth factor-induced growth inhibition requires Stat1 activation.

J E Darnell, J. Darnell, J. Bromberg, 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab.

G. Mills, J. Mendelsohn, Z. Siddik, 2007, Cancer research.

Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.

L. Norton, J. Baselga, J. Albanell, 1998, Cancer research.

Growth factors in lung cancer. Current status and implications for therapy

J. Mendelsohn, S. Grant, S. Lynch, 1997 .

Regulation of phosphorylation of the c-erbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells

R. Kumar, J. Mendelsohn, H. Shepard, 1991 .

Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials.

Funda Meric-Bernstam, Gordon B Mills, Michael A Davies, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Innovative clinical trials for development of personalized cancer medicine

R. Schilsky, J. Mendelsohn, U. Ringborg, 2015, Molecular oncology.

Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin.

N. Rosen, J. Mendelsohn, Z. Fan, 1995, The Journal of clinical investigation.

Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.

C. Hudis, L. Norton, J. Baselga, 1999, Seminars in oncology.

Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy.

J. Mendelsohn, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Growth regulation of human renal carcinoma cells: role of transforming growth factor alpha.

J. Baselga, R. Kumar, W. Fair, 1992, Cancer research.

Regulation of phosphorylation of the c-erbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells

R. Kumar, H. Shepard, J. Mendelsohn, 1991, Molecular and cellular biology.

Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies.

J. Mendelsohn, Z. Fan, H. Masui, 1993, Cancer research.

Mitogenic action of tumor necrosis factor in human fibroblasts: Interaction with epidermal growth factor and platelet‐derived growth factor

J. Mendelsohn, J. Vilček, V. Palombella, 1988, Journal of cellular physiology.

Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth.

G. Tortora, F. Ciardiello, J. Mendelsohn, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Prolonged induction of p21Cip1/WAF1/CDK2/PCNA complex by epidermal growth factor receptor activation mediates ligand-induced A431 cell growth inhibition

A. Deblasio, J. Mendelsohn, Z. Fan, 1995, The Journal of cell biology.

Expression of epidermal growth factor receptor and human papillomavirus E6/E7 proteins in cervical carcinoma cells.

Wenbiao Liu, M. Andreeff, J. Mendelsohn, 1997, Journal of the National Cancer Institute.

Expression of Epidermal Growth Factor Receptor and Human Papillomavirus E 6 / E 7 Proteins in Cervical Carcinoma Cells

L. Ellis, Wenbiao Liu, M. Andreeff, 1997 .

A direct radioimmunoassay for human epidermal growth factor receptor using 32P-autophosphorylated receptor.

C. Macleod, J. Mendelsohn, H. Sunada, 1985, Analytical biochemistry.

EGF receptors as a target for cancer therapy.

J. Mendelsohn, 2004, Transactions of the American Clinical and Climatological Association.

Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain.

J. Mendelsohn, G. Apell, H. Kamrath, 1989, Cancer research.

Regulation of Cyclooxygenase-2 pathway by HER2 receptor

M. Mandal, J. Mendelsohn, Rakesh Kumar, 1999, Oncogene.

Role of 2′-5′-Oligoadenylate Synthetase in γ-Interferon-mediated Growth Inhibition of A431 Cells

J. Mendelsohn, Rakesh Kumar, Rakesh Kumar, 1989 .

Growth regulation of A431 cells. Modulation of expression of transforming growth factor-alpha mRNA and 2',5'-oligoadenylate synthetase activity.

R. Kumar, J. Mendelsohn, 1990, The Journal of biological chemistry.

Development of a Targeted Treatment for Cancer

J. Mendelsohn, 2008 .

Crosstalk between epidermal growth factor receptor and P-glycoprotein in actinomycin D-resistant Chinese hamster lung cells.

J. Mendelsohn, M. B. Meyers, P. Yu, 1993, Biochemical pharmacology.

Imaging of human tumor xenografts with an indium-111-labeled anti-epidermal growth factor receptor monoclonal antibody.

J. Mendelsohn, C. Divgi, K. Pentlow, 1989, Journal of the National Cancer Institute.

Growth factor receptors as targets for antitumor therapy with monoclonal antibodies.

J. Mendelsohn, 1988, Progress in allergy.

Anti-epidermal growth factor receptor monoclonal antibody cetuximab plus Doxorubicin in the treatment of metastatic castration-resistant prostate cancer.

H. Scher, M. Kattan, J. Mendelsohn, 2009, Clinical genitourinary cancer.

The epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies.

J. Mendelsohn, 1990, Seminars in cancer biology.

Requirement of hypoxia-inducible factor-1α down-regulation in mediating the antitumor activity of the anti–epidermal growth factor receptor monoclonal antibody cetuximab

J. Mendelsohn, K. Liang, Z. Fan, 2008, Molecular Cancer Therapeutics.

Reduced growth rate accompanied by aberrant epidermal growth factor signaling in drug resistant human breast cancer cells.

S. Bates, J. Mendelsohn, P. Bishop, 2000, Biochimica et biophysica acta.

Antibody-mediated EGF receptor blockade as an anticancer therapy: from the laboratory to the clinic

J. Mendelsohn, 2003, Cancer Immunology, Immunotherapy.

Relation of epidermal growth factor receptor concentration to growth of human epidermoid carcinoma A431 cells.

J. Mendelsohn, A. Le, G. Gill, 1984, The Journal of biological chemistry.

Effects of epidermal growth factor receptor concentration on tumorigenicity of A431 cells in nude mice.

J. B. Santon, M. Cronin, C. Macleod, 1986, Cancer research.

Effects of epidermal growth factor receptor concentration on tumorigenicity of A431 cells in nude mice.

J. B. Santon, M. Cronin, C. Macleod, 1986, Cancer research.

Functional consequence of the MET-T1010I polymorphism in breast cancer

G. Mills, P. Brown, G. Hortobagyi, 2014, Oncotarget.

Precision Medicine Clinical Trials: Successes and Disappointments, Challenges and Opportunities – Lessons Learnt

J. Sicklick, R. Schilsky, W. Symmans, 2018, Predictive Biomarkers in Oncology.

Curbing tobacco's toll starts with the professionals: World No Tobacco Day

H. Klocker, P. Boyle, A. Berns, 2005, The Lancet.

Growth inhibition of human colon carcinoma cells by combinations of anti-epidermal growth factor-related growth factor antisense oligonucleotides.

N. Normanno, G. Tortora, C. Bianco, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

The epidermal growth factor receptor as a target for therapy in breast carcinoma

J. Baselga, J. Mendelsohn, 2004, Breast Cancer Research and Treatment.

Growth Inhibition of Human Tumor Cells in Athymic Mice by Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies 1

J. Mendelsohn, J. Sato, B. Wolf, 2006 .

Use of an antibody to target geldanamycin.

J. Mendelsohn, 2000, Journal of the National Cancer Institute.

EDITORIALS Use of an Antibody to Target Geldanamycin

J. Mendelsohn, 2000 .

Involvement of B lymphocytes in the growth inhibition of human pulmonary melanoma metastases in athymic nu/nu mice by an antibody-lymphotoxin fusion protein.

J. Becker, J. Mendelsohn, S. Gillies, 1996, Cancer research.

Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins.

J. Becker, J. Mendelsohn, S. Gillies, 1996, Proceedings of the National Academy of Sciences of the United States of America.

Epidermal growth factor receptor expression in human lung carcinomas defined by a monoclonal antibody.

J. Mendelsohn, I. Royston, H. Masui, 1987, Journal of the National Cancer Institute.

Prolonged Induction of p21CiplmAFI/CDK2/PCNA Complex by Epidermal Growth Factor Receptor Activation Mediates Ligand-induced A431 Cell Growth Inhibition

A. Deblasio, J. Mendelsohn, Z. Fan, 2002 .

Ligand induced internalization of epidermal growth factor receptors by A431 cells decreases at high cell densities in culture.

J. Mendelsohn, H. Sunada, J. Peacock, 1991, Growth factors.

Commentary on "Recombinant Humanized Anti-HER2 Antibody (Herceptin) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2/neu Overexpressing Human Breast Cancer Xenografts" (A Follow Up).

J. Mendelsohn, 2016, Cancer research.

Regulation of epidermal growth factor receptor in NIH3T3/HER14 cells by antireceptor monoclonal antibodies.

R. Kumar, J. Mendelsohn, Z. Fan, 1993, The Journal of biological chemistry.

Effects of epidermal growth factor on transferrin receptor phosphorylation and surface expression in malignant epithelial cells

C. Macleod, J. Mendelsohn, H. Sunada, 1987, Journal of cellular physiology.

Effects of Antiepidermal Growth Factor Receptor Antibody 528 on the Proliferation and Differentiation of Head and Neck Cancer

E. Sturgis, J. Mendelsohn, S. Schantz, 1994 .

Effects of antiepidermal growth factor receptor antibody 528 on the proliferation and differentiation of head and neck cancer.

E. Sturgis, J. Mendelsohn, S. Schantz, 1994, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

Personalized cancer medicine – A strategy to counteract an increasing cancer challenge

R. Schilsky, J. Mendelsohn, U. Ringborg, 2012, Molecular oncology.

Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation.

M. Melamed, F. Real, L. Old, 1986, Cancer research.

Receptor blockade with monoclonal antibodies as anti-cancer therapy.

J. Baselga, J. Mendelsohn, 1994, Pharmacology & therapeutics.

The carbohydrate specificities of the monoclonal antibodies 29.1, 445 and 3C1B12 to the epidermal growth factor receptor of A431 cells

T. Libermann, I. Lax, J. Schlessinger, 1985, Bioscience reports.

EGF induces cell cycle arrest of A431 human epidermoid carcinoma cells

M. Cronin, C. Macleod, J. Mendelsohn, 1986, Journal of cellular physiology.

Polypeptide growth factors in the regulation of human tumor cell proliferation

R. Kumar, J. Mendelsohn, Rakesh K. Kumar, 1991, Current opinion in oncology.

Reciprocal changes in p27(Kip1) and p21(Cip1) in growth inhibition mediated by blockade or overstimulation of epidermal growth factor receptors.

J. Chou, J. Mendelsohn, Z. Fan, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Coexpression of the HER-2 gene product, p185HER-2, and epidermal growth factor receptor, p170EGF-R, on epithelial ovarian cancers and normal tissues.

R. Bast, A. Berchuck, J. Mendelsohn, 1998, Hybridoma.

Toxicity of ligand and antibody‐directed ricin A‐chain conjugates recognizing the epidermal growth factor receptor

A. Vollmar, J. Mendelsohn, D. Banker, 1987, Journal of cellular physiology.

Ceramide stimulates epidermal growth factor receptor phosphorylation in A431 human epidermoid carcinoma cells. Evidence that ceramide may mediate sphingosine action.

J. Mendelsohn, R. Kolesnick, N. Radin, 1991, The Journal of biological chemistry.

Vascular endothelial growth factor up-regulation via p21-activated kinase-1 signaling regulates heregulin-beta1-mediated angiogenesis.

R. Kumar, J. Mendelsohn, R. Vadlamudi, 2000, The Journal of biological chemistry.

Mendelsohn : The EGF receptor as a target for cancer therapy and forms of thyroid

J. Mendelsohn, 1994 .

Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes.

J. Mendelsohn, H. Masui, T. Moroyama, 1986, Cancer research.

Receptor blockade with monoclomal antibodies as anti-cancer therapy

J. Baselga, J. Mendelsohn, 1994 .

Modulation of tyrosine, serine, and threonine phosphorylation and intracellular processing of the epidermal growth factor receptor by antireceptor monoclonal antibody

J. Mendelsohn, H. Sunada, J. Peacock, 1990, Journal of cellular physiology.

Anti-epidermal growth factor receptor monoclonal antibodies may inhibit A431 tumor cell proliferation by blocking an autocrine pathway.

J. Mendelsohn, A. Goldenberg, H. Masui, 1987, Transactions of the Association of American Physicians.

Therapeutic application of anti‐growth factor receptor antibodies

J. Mendelsohn, Z. Fan, 1998, Current opinion in oncology.

JEREMIAH TARGETED CANCER THERAPY

J. Mendelsohn, Go R. Sato, J. Metzger, 2007 .

HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells

G. Mills, J. Mendelsohn, K. Liang, 2003, Oncogene.

Altered epidermal growth factor signal transduction in activated Ha-ras-transformed human keratinocytes.

J. Rhim, J. Mendelsohn, M. Clawson, 1993, Biochemical and biophysical research communications.

Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells.

R. Bast, M. Conaway, J. Mendelsohn, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

EGF receptor and p185erbB‐2‐specific single‐chain antibody toxins differ in their cell‐killing activity on tumor cells expressing both receptor proteins

E. Kornilova, B. Groner, N. Hynes, 1995, International journal of cancer.

Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts.

J. Baselga, J. Mendelsohn, Z. Fan, 1993, Cancer research.

Reciprocal Changes in 27 Kq and p 2 lC in Growth Inhibition Mediated by Blockade or Overstimulation of Epidermal Growth Factor Receptors 1

J. Chou, J. Mendelsohn, Z. Fan, 2005 .

EGF Receptor Inhibition by Antibody as Anticancer Therapy

J. Chou, J. Baselga, J. Mendelsohn, 1997 .

AND EGF RECEPTOR BLOCKADE

J. Baselga, J. Mendelsohn, Z. Fan, 1996 .

Combination Therapy with Cisplatinum and EGF Receptor Blockade

J. Baselga, J. Mendelsohn, Z. Fan, 1996 .

Anti-epidermal growth factor receptor monoclonal antibodies as potential anti-cancer agents

J. Mendelsohn, 1990, The Journal of Steroid Biochemistry and Molecular Biology.

Growth factors in human cancer.

J. Gabrilove, J. Mendelsohn, 1990, Current opinion in oncology.

Anti-EGF receptor monoclonal antibodies: biological studies and potential clinical applications.

J. Mendelsohn, John Mendelsohn, 1989, Transactions of the American Clinical and Climatological Association.

Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145.

H. Scher, J. Mendelsohn, Z. Fan, 1996, Cancer research.

Epidermal growth factor receptor monoclonal antibody inhibits constitutive receptor phosphorylation, reduces autonomous growth, and sensitizes androgen-independent prostatic carcinoma cells to tumor necrosis factor alpha.

J. Mendelsohn, Chung-Ta Lee, E. Sherwood, 1992, Cancer research.

Cooperative antiproliferative effects of 8-chloro-cyclic AMP and 528 anti-epidermal growth factor receptor monoclonal antibody on human cancer cells.

J. Baselga, P. Tagliaferri, M. Caraglia, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity.

J. Mendelsohn, J. Sato, C. Cochet, 1984, The Journal of biological chemistry.

Autocrine Regulation of Membrane Transforming Growth Factor- Cleavage (*)

J. Baselga, A. Pandiella, J. Mendelsohn, 1996, The Journal of Biological Chemistry.

Regulation of TGF‐α expression in human keratinocytes: PKC‐dependent and ‐independent pathways

James T. Elder, J. Voorhees, J. Mendelsohn, 1992 .

Expression of the transforming growth factor-alpha/epidermal growth factor receptor pathway in normal human breast epithelial cells.

S. Bates, J. Mendelsohn, R. Dickson, 1990, Endocrinology.

Involvement of p21Waf1 in mediating inhibition of paclitaxel-induced apoptosis by epidermal growth factor in MDA-MB-468 human breast cancer cells.

J. Mendelsohn, B. Liu, Y. Lu, 2000, Anticancer research.

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

L. Norton, J. Baselga, D. Pfister, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody.

J. Mendelsohn, J. Sato, G H Sato, 1983, Proceedings of the National Academy of Sciences of the United States of America.

Regulation of TCF-cx Expression in Human Keratinocytes : PKC-Dependent and-Independent Pathways

James T. Elder, Klein, J. Voorhees, 2004 .

Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer

G. Mills, K. Do, Shunqiang Li, 2018, Molecular Cancer Therapeutics.

Monoclonal Antibodies Directed towards Growth-Related Receptors on Human Tumors

C. Macleod, J. Mendelsohn, I. Trowbridge, 1985 .

Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms.

C. Cordon-Cardo, V. Reuter, H. Scher, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

The role of growth factor signaling in malignancy.

R. Herbst, J. Mendelsohn, A. Onn, 2003, Cancer treatment and research.

Effect of transforming growth factor-beta 1 on proliferation and induction of hemoglobin accumulation in K-562 cells.

J. Mendelsohn, L. L. Chen, A. Dean, 1989, Blood.

Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.

G. Tortora, F. Ciardiello, R. Bianco, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model.

N. Goldstein, J. Mendelsohn, M. Prewett, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies.

J. Mendelsohn, J. Sato, J D Sato, 1984, Cancer research.

Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors.

J. Mendelsohn, J. Sato, T. Kawamoto, 1983, Molecular biology & medicine.

Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation.

G. Mills, G. Hortobagyi, M. Hung, 2010, Cancer cell.

ALK: a tyrosine kinase target for cancer therapy

Md Abu Shufean, Amber M. Johnson, Nora S. Sanchez, 2017, Cold Spring Harbor molecular case studies.

Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis.

Razelle Kurzrock, Brian Leyland-Jones, Melissa Zhao, 2016, JAMA oncology.

Clinical outcomes based on multigene profiling in metastatic breast cancer patients

G. Mills, F. Meric-Bernstam, A. Sahin, 2016, Oncotarget.

Regulation of Elongation Factor-1α Expression by Growth Factors and Anti-receptor Blocking Antibodies*

M. Mandal, J. Mendelsohn, Rakesh Kumar, 2001, The Journal of Biological Chemistry.

Expression of the transforming growth factor-alpha/epidermal growth factor receptor pathway in normal human breast epithelial cells.

S. Bates, J. Mendelsohn, R. Dickson, 1990, Endocrinology.

Constitutive overexpression of cyclin D1 in human breast epithelial cells does not prevent G1 arrest induced by deprivation of epidermal growth factor

J. Chou, N. Rosen, J. Mendelsohn, 1999, Breast Cancer Research and Treatment.

Clinical actionability enhanced through deep targeted sequencing of solid tumors.

Yuan Qi, Ken Chen, Zechen Chong, 2015, Clinical chemistry.

Implementation of biomarker-driven cancer therapy: existing tools and remaining gaps.

Ken Chen, Funda Meric-Bernstam, Gordon B Mills, 2014, Discovery medicine.

Precision Oncology Decision Support: Current Approaches and Strategies for the Future

Funda Meric-Bernstam, Gordon B Mills, Elmer V Bernstam, 2018, Clinical Cancer Research.

Epidermal growth factor receptor targeting in cancer.

John Mendelsohn, J. Baselga, J. Mendelsohn, 2006, Seminars in oncology.

CCR 20th Anniversary Commentary: A Chimeric Antibody, C225, Inhibits EGFR Activation and Tumor Growth

N. Goldstein, J. Mendelsohn, M. Prewett, 2015, Clinical Cancer Research.

Formation of p27-CDK complexes during the human mitotic cell cycle.

A. Deblasio, A. Giordano, J. Mendelsohn, 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

Clinical Use of Precision Oncology Decision Support.

Kenna R Mills Shaw, Funda Meric-Bernstam, Gordon B Mills, 2017, JCO precision oncology.

Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c- jun N-terminal kinase activity

J. Mendelsohn, Z. Fan, B. Liu, 2000, British Journal of Cancer.

Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol.

Ann M. Bailey, Yuan Qi, Y. Qi, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Regulation of TGF-alpha expression in human keratinocytes: PKC-dependent and -independent pathways.

James T. Elder, J. Voorhees, J. Mendelsohn, 1992, Journal of cellular physiology.

Building a personalized medicine infrastructure at a major cancer center.

Funda Meric-Bernstam, Gordon B Mills, John Mendelsohn, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Basic fibroblast growth factor causes growth arrest in MCF-7 human breast cancer cells while inducing both mitogenic and inhibitory G1 events.

A. Deblasio, J. Mendelsohn, H. Wang, 1997, Cancer research.

Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments.

J. Baselga, R. Nicholson, F. Rojo, 2001, Cancer research.

From combinatorial peptide selection to drug prototype (II): Targeting the epidermal growth factor receptor pathway

Wadih Arap, Renata Pasqualini, Richard L. Sidman, 2010, Proceedings of the National Academy of Sciences.

The impact of tumor heterogeneity on patient treatment decisions.

Funda Meric-Bernstam, Gordon B Mills, John Mendelsohn, 2013, Clinical chemistry.

Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells.

J. Mendelsohn, Z. Fan, Y. Lu, 1994, The Journal of biological chemistry.

Nuclear targeting of Bax during apoptosis in human colorectal cancer cells

M. Mandal, J. Mendelsohn, Rakesh Kumar, 1998, Oncogene.

Differential modulation of paclitaxel-mediated apoptosis by p21Waf1 and p27Kip1

J. Mendelsohn, Z. Fan, Mathias Schmidt, 2000, Oncogene.

Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.

G. Fontanini, G. Tortora, F. Ciardiello, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies.

L. Norton, J. Baselga, W. Miller, 1993, Journal of the National Cancer Institute.

Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial

J Jack Lee, Eitan Rubin, Razelle Kurzrock, 2019, Nature Medicine.

Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide.

G. Tortora, F. Ciardiello, R. Bianco, 1998, Journal of the National Cancer Institute.

Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A.

G. Fontanini, G. Tortora, C. Bianco, 1996, Journal of the National Cancer Institute.

Personalizing oncology: perspectives and prospects.

J. Mendelsohn, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Augmentation of a humanized Anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225

J. Mendelsohn, Z. Fan, D. Ye, 1999, Oncogene.

Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial.

R. Schilsky, J. Lee, R. Berger, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program

Harold L. Moses, Sharyl J. Nass, John Mendelsohn, 2010 .

In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody.

K. Ang, J. Mendelsohn, L. Milas, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Epidermal growth factor receptor family and chemosensitization.

J. Mendelsohn, Z. Fan, 1997, Journal of the National Cancer Institute.

Synergistic growth inhibition and induction of apoptosis by a novel mixed backbone antisense oligonucleotide targeting CRIPTO in combination with C225 anti-EGFR monoclonal antibody and 8-Cl-cAMP in human GEO colon cancer cells.

A. Casamassimi, N. Normanno, G. Tortora, 1999, Oncology reports.

Role of transforming growth factor-α-related peptides in the autocrine/paracrine control of experimental breast cancer growthin vitro by estradiol, prolactin, and progesterone

M. Herlyn, J. Mendelsohn, L. Demers, 1990, Breast Cancer Research and Treatment.

Type I Receptor Tyrosine Kinases as Targets for Therapy in Breast Cancer

John Mendelsohn, J. Baselga, J. Mendelsohn, 2004, Journal of Mammary Gland Biology and Neoplasia.

Breast Cancer Therapy Using Monoclonal Antibodies Against Epidermal Growth Factor Receptor and HER-2

J. Mendelsohn, Z. Fan, 1999 .

Autonomous proliferation of colon cancer cells that coexpress transforming growth factor α and its receptor

W. Karnes, J. Mendelsohn, Martín G. Martín, 1992 .

Autonomous proliferation of colon cancer cells that coexpress transforming growth factor alpha and its receptor. Variable effects of receptor-blocking antibody.

W. Karnes, J. Mendelsohn, J. G. Park, 1992, Gastroenterology.

Autonomous growth of androgen-independent human prostatic carcinoma cells: role of transforming growth factor alpha.

J. Mendelsohn, Chung Lee, E. Sherwood, 1991, Cancer research.

Anti-epidermal growth factor receptor antibodies inhibit the autocrine-stimulated growth of MDA-468 human breast cancer cells.

S. Bates, J. Schlessinger, J. Mendelsohn, 1989, Molecular endocrinology.

Targeted therapy for prostate cancer: the Memorial Sloan-Kettering Cancer Center approach.

H. Scher, N. Rosen, J. Mendelsohn, 1996, Seminars in oncology.

Circulating tumor cells in breast cancer: Advanced tools for “tailored” therapy?

J. Mendelsohn, M. Cristofanilli, 2006, Proceedings of the National Academy of Sciences.

Physical Interaction between Epidermal Growth Factor Receptor and DNA-dependent Protein Kinase in Mammalian Cells*

M. Mandal, J. Mendelsohn, Rakesh Kumar, 1998, The Journal of Biological Chemistry.

The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression

J. Mendelsohn, Z. Fan, Yang Lu, 2005, Oncogene.

Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials.

J Jack Lee, Razelle Kurzrock, Richard L Schilsky, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Physician interpretation of genomic test results and treatment selection

Kenna R Mills Shaw, Funda Meric-Bernstam, Gordon B Mills, 2018, Cancer.

Prevalence of incidental actionable germline mutations in 1,000 advanced cancer patients on a prospective somatic genomic profiling program.

G. Mills, Y. Qi, L. Strong, 2015 .

Targeting the epidermal growth factor receptor for cancer therapy.

J. Mendelsohn, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Status o f E pidermal G rowth F actor R eceptor A ntagonists i n the B iology a nd T reatment o f C ancer

J. Baselga, J. Mendelsohn, 2003 .

Tumor receptor imaging: proceedings of the National Cancer Institute workshop, review of current work, and prospective for further investigations.

C. Osborne, R. Reba, R. Coleman, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

Beyond BRAFV600: clinical mutation panel testing by next-generation sequencing in advanced melanoma

Jared C Malke, G. Mills, K. Aldape, 2014, The Journal of investigative dermatology.

A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory

Amber M. Johnson, Nora S. Sanchez, Ann M. Bailey, 2017, Oncotarget.

The Molecular Basis of Cancer

Joe W. Gray, Mark A. Israel, John Mendelsohn, 1985 .

Mechanisms of growth inhibition by anti-transferrin receptor monoclonal antibodies.

J. Mendelsohn, R. Taetle, J. Castagnola, 1986, Cancer research.

Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody.

M. Rubin, J. Mendelsohn, Z. Fan, 1996, Oncogene.

Consumption of EGF by A431 cells: evidence for receptor recycling

J. Mendelsohn, H. Masui, L. Castro, 1993, The Journal of cell biology.

Extensive disease small cell carcinoma of the lung. Trial of non‐cross resistant chemotherapy and consolidation radiotherapy

J. Koziol, J. Mendelsohn, R. Dillman, 1982, Cancer.

Clinical next generation sequencing to identify actionable aberrations in a phase I program

Amber M. Johnson, K. Baggerly, G. Mills, 2014, Oncotarget.

The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors.

E. Dmitrovsky, V. Rusch, J. Mendelsohn, 1996, Cytokine & growth factor reviews.

PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner.

J. Baselga, J. Albanell, D. W. Fry, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval.

R. Schilsky, J. Lee, A. Eggermont, 2015, Journal of the National Cancer Institute.

Monoclonal antibodies against the receptor for epidermal growth factor as potential anticancer agents

C. Macleod, J. Mendelsohn, H. Sunada, 1987 .

9-Cis retinoic acid inhibits growth of breast cancer cells and down-regulates estrogen receptor RNA and protein.

M. Rubin, W. Miller, J. Mendelsohn, 1994, Cancer research.

Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27Kip1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells.

J. Mendelsohn, Z. Fan, D. Ye, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies.

J. Mendelsohn, 1992, Journal of the National Cancer Institute. Monographs.

WIN Consortium—challenges and advances

John Mendelsohn, R. Schilsky, V. Lazar, 2011, Nature Reviews Clinical Oncology.

Heregulin Regulates Cytoskeletal Reorganization and Cell Migration through the p21-activated Kinase-1 via Phosphatidylinositol-3 Kinase*

J. Mendelsohn, Rakesh Kumar, J. Chernoff, 1998, The Journal of Biological Chemistry.

Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study.

K. Hess, F. Meric-Bernstam, P. Hwu, 2017, JCO precision oncology.

The Molecular Basis of Cancer: Fourth Edition

J. Gray, M. Israel, P. Howley, 2014 .

Blockage of EGF receptor signal transduction causes reversible arrest of normal and immortal human mammary epithelial cells with synchronous reentry into the cell cycle.

P. Yaswen, J. Mendelsohn, J. Bartholomew, 1993, Experimental cell research.

Expression of Epidermal Growth Factor Receptor in Human Cultured Cells and Tissues: Relationship to Cell Lineage and Stage of Differentiation1

M. Melamed, F. Real, L. Old, 2006 .

Expression of Epidermal Growth Factor Receptor in Human Cultured Cells and Tissues : Relationship to Cell Lineage and Stage of Differentiation 1

M. Melamed, F. Real, L. Old, 2006 .

Vascular Endothelial Growth Factor Up-regulation via p21-activated Kinase-1 Signaling Regulates Heregulin-β1-mediated Angiogenesis*

John Mendelsohn, J. Mendelsohn, Rakesh Kumar, 2000, The Journal of Biological Chemistry.

Transforming Growth Factor fi Modulates Phosphorylation of the Epidermal Growth Factor Receptor and Proliferation of A 431 Cells ’

J. Mendelsohn, T. Goldkorn, 2005 .

Transforming growth factor beta modulates phosphorylation of the epidermal growth factor receptor and proliferation of A431 cells.

J. Mendelsohn, T. Goldkorn, John Mendelsohn, 1992, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer.

F. Khuri, W. Hong, R. Perez-soler, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer.

F. Khuri, W. Hong, D. Shin, 2001, Clinical Cancer Research.

Effects of monoclonal antibodies that block transferrin receptor function on the in vivo growth of a syngeneic murine leukemia.

J. Mendelsohn, I. Trowbridge, C. Sauvage, 1987, Cancer research.

Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma

J. Mendelsohn, M. Naramura, S. Gillies, 1993, Cancer Immunology, Immunotherapy.

The Willet F. Whitmore, Jr., Lectureship: blockade of epidermal growth factor receptors as anticancer therapy.

C. Dinney, J. Mendelsohn, John Mendelsohn, 2001, The Journal of urology.

The epidermal growth factor receptor as a target for cancer therapy.

J. Mendelsohn, 2001, Endocrine-Related Cancer.

Blockade of receptors for growth factors: an anticancer therapy--the fourth annual Joseph H Burchenal American Association of Cancer Research Clinical Research Award Lecture.

J. Mendelsohn, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Serine phosphorylation of paxillin by heregulin-β1: role of p38 mitogen activated protein kinase

J. Mendelsohn, Rakesh Kumar, R. Vadlamudi, 1999, Oncogene.

The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma.

N. Goldstein, H. Scher, R. Rockwell, 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Mechanisms of cellular cytotoxicity mediated by a recombinant antibody-IL2 fusion protein against human melanoma cells.

J. Mendelsohn, M. Naramura, S. Gillies, 1993, Immunology letters.

Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide.

G. Tortora, F. Ciardiello, R. Bianco, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Customized Cancer Treatment: A Systems Biology Approach to Drug Selection

J. Trent, A. Califano, J. Mendelsohn, 2011 .

Insulin‐like growth factors modulate the growth inhibitory effects of retinoic acid on MCF‐7 breast cancer cells

K J Cullen, N. Rosen, W. Miller, 1995, Journal of cellular physiology.

Reduced expression of c-erbB2 gene product in human mammary carcinoma SK-BR-3 cells treated with interferon-gamma and tumor necrosis factor-alpha.

R. Kumar, J. Mendelsohn, 1994, Anticancer research.

Ligand-induced activation of A431 cell epidermal growth factor receptors occurs primarily by an autocrine pathway that acts upon receptors on the surface rather than intracellularly.

R. Kumar, J. Mendelsohn, M. Van de Vijver, 1991, The Journal of biological chemistry.